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Osteopontin (OPN) was described for the first time as a potential marker of neoplastic transformation by Senger et 
al. in 1979. Studies suggesting an important role of OPN in oncology, allergology, nephrology and cardiology have 
been published for many years. However, the largest number of articles pertains to the role of OPN in neoplastic 
transformation and will surely facilitate future determination of OPN levels in blood or cancer tissues with the pur-
pose of disease diagnosing, staging, prognosing metastases and monitoring the treatment effectiveness. Numerous 
studies showed that high OPN expression levels accompany metastases formation; the protein was also confirmed 
to be involved in stimulation of cell proliferation and formation of new blood vessels, i.e. angiogenesis. 
OPN was also shown to be capable of binding the CD-44 receptors, which facilitates migration and invasion of cancer 
cells into the blood vessels. Correlation was also demonstrated between OPN expression and the time to disease 
recurrence and overall survival in patients with breast cancer, gastric cancer, hepatocellular cancer, hormone-depen-
dent prostate cancer, kidney cancer and endometrial cancer. 
The exact mechanism responsible for OPN’s role in neoplastic transformation remains unclear and numerous research 
studies are conducted in this area. 
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Introduction
Osteopontin (OPN) was described for the first time by 
Senger et al. (1979), who indicated its role as a potential 
marker of epithelial cell transformation [1]. The name of OPN 
is associated with its function in the bone tissue [2]. There is 
evidence that OPN detected in transformed cells is exactly 
the same protein that enables osteoclast localization in the 
extracellular bone matrix [3].
OPN is a highly phosphorylated and glycosylated hydro-
philic protein, and it is composed of approximately 300 ami-
no acids. The specific amino acid sequence of Arg-Gly-Asp 
(RGD) mediates the OPN’s ability to bind to cells. Moreover, 
OPN has elements that bind calcium and hydroxyapatite, as 
well as two domains suitable for heparin [4]. 
Many forms of OPN of various particle size have been 
discovered so far, and the molecular mass of OPN ranges 
from 44 kDa to 75 kDa. Human OPN is encoded by a single 
gene consisting of 7 exons, which is located on the long 
arm of the chromosome 4 (4q13) [5, 6]. Initially, OPN was 
classified as a bone sialoprotein [7], and it was also referred 
to as Eta-1, secreted phosphoprotein, or uropontin [8]. The 
cDNA sequence that encodes OPN is similar in different 
mammals [9]. Recently, OPN was detected in animal milk, 
and it turned out that it had many similarities with human 
lactoferrin, which might be of importance regarding its 
possible use in the production of infant formulas. The vari-
ability of the native OPN structure is dependent on numer-
ous post-translational modifications, such as glycosylation 
and phosphorylation [10]. Due to the presence of the RGD 
sequence, OPN belongs to a class of proteins that interact 
with the surface of different cell types by binding to integrin 
receptors [11]. Another amino acid sequence of OPN enables 
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the interaction with cells expressing CD44 [12]. OPN binds 
to the cellular surface, which results in cell migration and 
adhesion [13]. 
Moreover, OPN plays a role in a number of physiologi-
cal and pathological processes, such as maintenance and 
remodeling of bone integrity in response to tension or pres-
sure, early cell immune reactions, dystrophic calcifications, 
recurrent coronary artery stenosis, regulation of growth and 
differentiation of cancer cells, and development of metasta-
ses [14]. It has also been shown that OPN takes part in the 
process of new vessel formation, i.e. angiogenesis, through a 
paracrine promotion of prostaglandin E2 (PGE2) binding to 
cell receptors on endothelial cells and other proangiogenic 
particles. Furthermore, OPN takes part in cell adhesion, 
apoptosis, inflammatory processes, and wound healing [15]. 
OPN is secreted into bodily fluids such as blood, urine, milk, 
bile and semen [16].
Under physiological conditions, OPN is expressed by 
osteoclasts, osteoblasts, teeth, endothelial cells of the mam-
mary glands, kidneys, pancreas, gall bladder, bronchi, sali-
vary glands, skin, nerve cells, endothelium, T lymphocytes, 
NK cells, macrophages, Kupffer cells, epithelial cells of the 
alimentary tract, urinary epithelium, and genital epithelium 
[17, 18]. An increased expression of OPN has been noted in 
acute and chronic inflammatory states, which is accompa-
nied by OPN expression by T lymphocytes, dendritic cells, 
macrophages, and NK cells [19, 20]. 
 OPN plays an important role in both acute and chronic 
inflammatory states [21] — it mediates the migration of 
macrophages and dendritic cells into the sites of inflamma-
tion [22], induces IL-12, IFN-γ production by macrophages 
and at the same time inhibits IL-10 secretion by these cells 
[23]. It has been determined that OPN induces an early 
cell-mediated immune response through the stimulation 
of cytokine production by Th1 lymphocytes and inhibition 
of Th2 lymphocytes [24]. OPN is regarded as one of the 
pro-inflammatory cytokines [25] and its secretion is regu-
lated by the pro-inflammatory/anti-inflammatory cytokine 
system [26]. 
Osteopontin and angiogenesis 
Vascular support is an important feature of both normal 
and pathological tissue structures as it enables tissue deve-
lopment, homeostasis with the surrounding environment 
by providing essential structural and energetic nutrients 
and oxygen. The process of new vessel formation unfolds 
in many stages and is regulated by numerous cytokines, 
enzymes, and other factors that stimulate or inhibit the 
formation of capillaries. Angiogenesis is a complex process 
that involves degradation of extracellular matrix, and sub-
sequent activation, proliferation, and migration of endo-
thelial cells and pericytes [27, 28]. Although angiogenesis 
does occur under physiological conditions (menstrual cycle, 
pregnancy, placenta formation, wound healing, etc.), it has 
been implicated in multiple disease processes such as most 
cancers, psoriasis, rheumatoid arthritis, endometriosis, sto-
mach ulcers, diabetic proliferative retinopathy, and ischemic 
heart disease [29–34]. 
Recent research suggests that OPN may also reveal sig-
nificant angiogenic properties [35]. OPN, through its binding 
to αvβ3 integrin, stimulates adhesion and migration of endo-
thelial cells [36]. It was demonstrated that endothelial cells 
express αvβ3 integrin after stimulation with growth factors, 
in inflammatory sites, in healing wounds, and in the vascu-
lature of certain tumors [37]. Moreover, OPN, as one of the 
extracellular matrix proteins, is able to inhibit endothelial 
cell apoptosis. The binding of OPN to αvβ3 integrin results in 
the activation of the transcription factor NF-κB, which plays a 
protective role in endothelial cell survival [38]. Furthermore, 
OPN directly interacts with vascular endothelial growth fac-
tor (VEGF) [39]. It has been demonstrated that VEGF causes 
an increased expression of αvβ3 integrin on the surface of 
endothelial cells, and induces OPN mRNA production. More-
over, it has been shown that OPN stimulates endothelial cell 
migration — endothelial cells that have been incubated with 
VEGF migrate faster after the addition of OPN. This might 
result from the fact that VEGF increases the expression of 
αvβ3 integrin on endothelial cell surface, which leads to an 
enhanced interaction with OPN [40]. 
Shijubo et al. (1999), in an immunohistochemical study, 
reported that VEGF and OPN were present in pulmonary 
adenocarcinoma samples and the greatest intensity of an-
giogenesis was associated with the presence of both VEGF 
and OPN [41]. Moreover, in patients undergoing surgery, 
VEGF and OPN were negative prognostic factors — the 
risk of recurrence was significantly higher in patients with 
a confirmed expression of either VEGF or OPN. Furthermore, 
a simultaneous expression of VEGF and OPN was associa-
ted with an even higher risk of recurrence. These results 
suggest that both VEGF and OPN have proangiogenic and 
pro-cancerous potential as their expression is associated 
with an increased risk of recurrence of pulmonary adeno-
carcinoma [41]. 
Leali et al. (2003) reported that the production of OPN is 
associated with fibroblast growth factor (FGF) — endothelial 
cells with a high expression of FGF2 are characterized by an 
increased expression of OPN [42]. 
Osteopotin and invasiveness of cancers
An increased cytoplasmic expression of OPN has been 
reported in lingual, esophageal, gastric, colon, pancreatic, 
renal, and endometrial cancer. OPN, through a paracrine 
action, triggers a number of signaling pathways in cancer 
cells, which result in the expression of potentially oncoge-
nic, prometastatic and proangiogenic substances, such as 
prostaglandin E2 (PGE2) and metalloproteinases 2 (MMP-2) 
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and 9 (MMP-9). Mi et al. (2009) demonstrated that ablation of 
OPN cell surface receptor binding is associated with signifi-
cant alteration in gene and protein expression critical in key 
carcinogenesis pathways. Many of these proteins have not 
been previously associated with OPN. OPN receptor bloc-
kage was associated with downregulation of interleukin-10 
(IL-10), vascular endothelial growth factor (VEGF), platelet 
derived growth factor (PDGF) and anti-apoptosis signaling 
with concomitant upregulation of apoptosis, granulocy-
te-macrophage colony stimulating factor (GM-CSF), anti-
-proliferative and anti-metastasis signaling pathways [43]. 
Numerous reports suggest that OPN plays an important 
role in the process of metastasizing, which requires from 
proteolytic capabilities of cancer cells enabling the degra-
dation of the extracellular matrix, subsequent migration, 
proliferation, and angiogenesis in the metastatic site. OPN 
is involved in all of these processes by binding to integrins 
in the basal membrane, and on the surface of leukocytes. 
Integrins mediate several processes leading to the formation 
of metastases, such as chemotaxis, phagocytosis, adhesion, 
migration, and proliferation of lymphocytes [44, 45]. Based 
on protein sequence information, research into cell sur-
face receptors focused on Arg-Gly-Asp (RGD)-dependent 
interactions of OPN, and these efforts led to the identifi-
cation of αvβ3, αvβ1, and αvβ5 integrins as OPN receptors. 
In addition, non-RGD-dependent interactions have since 
been described. The Leu-Pro-Val (LPV) containing domain 
of OPN is a site of interaction with α4β1, and a cryptic, Ser-
Val-Val-Tyr-Glu-Leu-Arg (SVVYGLR) domain that interacts 
with α9β1 following exposure by thrombin cleavage of 
intact human OPN has been identified. The conservation 
of the thrombin cleavage site in all the OPN sequences that 
have been determined suggests that cleavage is important 
in some necessary physiological process. It was discovered 
that for some cells of hematopoietic origin cleavage of OPN 
by thrombin enhanced its ability to promote adhesion, 
confirming earlier reports that for some cell types throm-
bin-cleaved OPN supported adhesion, spreading, and migra-
tion better than the intact molecule. OPN can also enhance 
cell survival and modulate phosphorylation of intracellular 
signal transduction intermediates such as focal adhesion 
kinase, paxillin, and Src [46, 47]. The binding to the integrins 
is also significant in the metastasis formation process in 
breast and prostate cancer [48, 49]. Similarly, the binding 
of OPN to the CD44 receptor may also promote the process 
of metastasizing by inducing migration and invasion of 
cancer cells [50]. Some studies suggest that cell migration 
induced by OPN results from the stimulation of urokinase 
plasminogen activator (uPA) — a proteolytic enzyme, which 
results in an increased proteolytic activity [51]. Following 
migration, cancer cells start to invade and proliferate in 
distant organs — this is stimulated by OPN that enhances 
cell proliferation indirectly through VEGF. Tumor growth 
requires a rich vascular supply, and it has been shown that 
OPN plays an important role in this process [52]. 
Chakraborty et al. (2008) demonstrated that OPN, 
through an autocrine and paracrine action, induces the 
expression of VEGF that results in angiogenesis [53]. Nu-
merous studies confirm a correlation between the time to 
recurrence or mortality rate and the serum concentration 
of OPN in various cancers, such as breast cancer, gastric 
cancer, hepatocellular cancer, hormone-dependent pros-
tate cancer, and cervical cancer — the greater was the OPN 
serum concentration, the shorter was the recurrence and 
survival time. In the analyzed studies, the expression of 
OPN correlated with lymph node metastasis and advanced 
TNM stage and histologic grade. Elevated OPN expression 
levels also correlated with tumor recurrence or metastasis. 
Overall, the expression of OPN was an independent prog-
nostic factor for both disease-free and overall survival of 
breast cancer patients [54]. OPN levels was also increased 
in patients with local recurrence, who were treated with 
primary radiotherapy for locally advanced head and neck 
squamous-cell carcinoma. Monitoring of increased levels 
of postoperative serum OPN concentration has also been 
proposed for assessing treatment response and tumor re-
currence after resection of hepatitis B-related hepatocellular 
carcinoma. In hepatocellular carcinoma tissues, OPN levels 
were found to be significantly higher in recurrent tumor tis-
sues compared to non-recurrent tissues. Also patients with 
higher OPN serum levels had significantly shorter median 
survival time and recurrence time compared to the ones 
with lower OPN levels [55]. Moreover, there is an association 
between OPN concentration and the stage of breast cancer, 
non-small-cell lung cancer, gastric cancer, hepatic cancer, 
prostate cancer, and melanoma [44]. In non-small-cell lung 
cancer and prostate cancer, the concentration of OPN is 
correlated with the presence of metastases in bones [45] 
and the disease stage. In the head and neck cancers, OPN 
concentration is associated with tissue hypoxia [48], which 
leads to disease recurrence [49] — the expression of the 
OPN gene is correlated with a high expression of the VHL 
gene that regulates hypoxia [50]. Certainly it appears that 
OPN concentration level has significant correlative relation-
ship with aggressive disease and poor prognosis. However, 
OPN is not a universal marker for tumors and metastasis. It 
is upregulated in response to stress and inflammation and 
hence its use is clinically not favored [56].
Takafuji et al. (2007) demonstrated that OPN was present 
in different molecular forms in the human hepatic carcinoma 
samples [57]. The smallest form — OPN 5 kDa correlated with 
cancer stage and induced cancer cell invasion by promoting 
binding to the CD44 receptor. The authors suggested that 
the increased expression of OPN-c during the process of 
metastasizing might result from the fact that it contains the 
OPN 5 kDa fragment. Therefore, OPN 5 kDa might be crucial 
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in the neoplastic transformation and become a potential 
treatment target [57]. 
CD44 plays a significant role in the tumor initiation and 
progression in colorectal cancer, but how the molecule 
benefits cancer cells from the tumor microenvironment, 
especially tumor-associated macrophages, remains poorly 
defined. OPN was highly expressed in hepatic metastasis 
from colorectal cancer compared to primary colorectal tis-
sue and adjacent normal mucosa. Exogenous expression 
of OPN in colorectal cells increased heterotypic adhesion 
with endothelial cells [58]. What is more, OPN induced by 
macrophages contributes to metachronous liver metasta-
sis in colorectal cancer [59]. A recent study reports on the 
reciprocal interactions between tumor-associated macro-
phages and CD44-positive colorectal cancer cells via OPN/
CD44 interaction. Rao et al. (2013) found that macrophages, 
when cultured with CD44-positive colorectal cancer cells, 
were able to produce higher levels of OPN, which in turn 
facilitated the tumorigenicity and clonogenicity of the co-
lorectal cancer. The knockdown of CD44, such as treatment 
with CD44 blocking antibodies, attenuated OPN secretion. 
OPN, through binding to its receptor CD44, activated c-
-jun-NH(2)-kinase signaling and caused the clonogenicity 
of colorectal cancer cells. What is more, tissue microarray 
data showed that OPN expression, in combination with 
CD44v6, has a negative correlation with colorectal cancer 
patient survival. These results suggest that the OPN-CD44 
interaction is important for colorectal cancer progression 
and could suit as a potential therapeutic target for the tre-
atment of colorectal cancer [60].
Regarding angiogenesis, studies have shown that OPN 
expression is strongly correlated with tumor microvessel 
density, and the OPN-derived peptide SVVYGLR potentiates 
tube formation in three-dimensional collagen gels [61]. This 
increase in angiogenesis may be through PI3K/AKT- and ERK-
-mediated pathways with VEGF acting as a positive feedback 
signal, as the inhibition of angiogenesis was stronger with an 
OPN-antibody than with a VEGF-antibody, or PI3K and ERK 
inhibitor [62]. Furthermore, Tang et al. (2007) showed that 
the proliferation, migration, and tube formation of human 
umbilical vein endothelial cells was reduced following OPN 
knockdown in gastric cancer cells [63]. Additional studies 
have also shown that the expression of some tumor-as-
sociated genes that play an important role in metastatic 
processes, such as VEGF, MMP-2, MMP-9, and μPA, are clo-
sely associated with OPN [64–66], which is likely one of 
numerous prognostic factors related to colorectal cancer 
metastasis [67].
Liu et al. (2010) have reported that OPN induces expression 
of MMP-2 and MMP-9 via NF-κB-mediated signaling pathways 
in prostate cancer [66]. In addition, the expression of MMP-2 
and MMP-9 is correlated with angiogenesis and metastasis of 
colorectal cancer [68]. Thus, OPN downregulation could inhibit 
not only the MMPs, but also VEGF and μPA expression in colon 
cancer cells, which might lead to decrease invasiveness and 
angiogenesis capacity of colorectal cancer cells. 
The fact that overexpression of OPN is associated with 
metastasis was also proved in the study by Huang et al. 
(2012). Results of this study showed the high influence of 
OPN overexpression on liver metastasis formation in col-
orectal cancer patients. The liver is the primary extra-colonic 
site for colorectal cancer metastasis and represents the 
most frequent location and clinical presentation for recur-
rent disease in patients who failed locoregional therapy. 
Furthermore, liver metastasis is a main cause of mortality 
from colorectal cancer. In the study by Huang et al. (2012) 
OPN mRNA was examined in tissues from colorectal cancer, 
adjacent normal mucosa, and liver metastasis. The OPN and 
its receptor expression were detected by using an immu-
nohistochemical methods. The expression of OPN mRNA in 
tumor tissues was significantly correlated with the colorectal 
cancer stages. OPN expression was also detected in normal 
hepatocytes surrounding colorectal cancer metastasis. Both 
known so far OPN receptors, integrin αv and CD44v6 pro-
teins, were strongly expressed in hepatocytes from normal 
liver. Colorectal cancer cells with intensified OPN expression 
exhibited increased heterotypic adhesion with endothelial 
cells and weakened intercellular communication. Because of 
OPN, homotypic adhesion ability is weakened in colorectal 
cancer cells and the cells to depart from primary site more 
easily, and enter the blood circulation. However, these cells 
are more easily to invade the extracellular matrix when 
heterotypic adhesion is enhanced. These two treads are 
important to metastasis in malignant cancer [69]. 
Diagnostic role of osteopontin 
Visintin et al. (2008) report that OPN, combined with 
other markers such as leptin, prolactin, insulin-like growth 
factor 2 (IGF-2), macrophage migration inhibitory factor 
(MIF), and cancer antigen 125 (CA-125), enhances diagno-
stic sensitivity to 95% and diagnostic specificity to 99% in 
ovarian cancer [70]. None of the biomarkers by themselves 
were good enough to differentiate healthy versus cancer 
cells. However, the combination of the six markers, and OPN 
among them, provided a better differentiation than only 
CA-125 assessment (sensitivity 72% at specificity 95%). OPN 
concentration in ovarian cancer patients was indeed signifi-
cantly greater than in healthy controls. In patients who un-
derwent chemotherapy, an increase in OPN concentration 
precedes clinical recurrence even when the concentration 
of CA-125 remains within the normal range [70]. 
Also in skin cancer, an increased OPN tissue expression 
was determined by immunohistochemistry in squamous 
cell carcinoma (SCC) and in precancerous cells and compa-
red to the healthy cells, although these findings were not 
unambiguous [71,72]. 
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The greatest number of reports links OPN to the process 
of metastasizing, which is reflected by a wide interest in 
the molecular mechanisms of OPN action. The molecular 
targets could enable the interference with the process of 
metastasizing and thereby lead to improved outcomes. It 
is astonishing how greatly is OPN’s structure modified po-
sttranslational. This leads to the development of different 
OPN forms characterized by various molecular mass that 
might play different roles in the process of metastasizing. 
The most coherent classification describes three different 
particles — OPN-a, OPN-b, and OPN-c [73]. In an invasi-
ve breast cancer cell line, only OPN-c has been detected, 
whereas it was not present in a non-invasive cell line or in 
healthy tissue. Moreover, OPN-c concentration is associated 
with cancer stage, and this form of OPN might be a marker 
of metastatic disease in various cancers [73]. 
The results of the study by Ting-Ting et al. (2014) show 
that compared with peri-carcinomatous tissues, abnormal 
expression of OPN occurs in the non-small-cell lung cancer 
(NSCLC) patient’s tissues, which indicates that OPN may par-
ticipate in the development of NSCLC. Moderately positive 
expression of OPN was found in 34.6% and strong expres-
sion in 47.5% of the NSCLCs. OPN expression in carcinomas 
was higher than in peri-carcinomatous tissues (p < 0.05). 
While no obvious association was observed with NSCLC 
patient age, gender, maximum diameter of the tumor and 
pathological type, OPN expression was more commonly 
detected in poorly differentiated carcinomas and these 
with lymph node metastasis, as well as at advanced clinical 
stage (p < 0.05). The expression of OPN in patients with 
regional lymph node metastasis was 93.0% and in patients 
without regional lymph node metastasis was 75.3%. Posi-
tive expression rates of patients of high, medium and low 
differentiation were 53.1%, 88.4% and 95.6% respectively. 
OPN expression was also positively correlated with micro-
-vascular density (MVD), namely, MVD count increased with 
high expression of OPN (p ≤ 0.001) [74].
These results show that abnormal expression of OPN is 
closely related with outside invasion and distant metastasis, 
but does not enhance the continued proliferation ability of 
tumor in a certain fixed position and affect the formation 
of ecological niche before metastasis. This phenomenon 
may result from the fact that OPN promotes the neovas-
cularization and lymphatic vessel, as well as the increase 
of vascular permeability and eventually causes lymphatic 
and blood metastasis.
The tumor MVD is used to suggest the quantity of neo-
vascularization and is a quantitative indicator of degree of 
tumor neovascularization, suggests the tumor recurrence, 
metastasis potential and long-term survival. The correlative 
analysis presented that OPN expression level was positively 
correlated with MVD expression in NSCLC (p < 0.01), which 
showed that OPN plays a very significant role in neovascu-
larization and may provide material basis for the vascula-
rization of tumor in the process of growth and metastasis 
of tumor, while vascularization further provides necessary 
pathways for the tumor cell metastasis [74].
OPN also seems to play an important multidirectional 
role in colorectal cancer, which is one of the most frequent 
malignant neoplasms worldwide and also one of the leading 
causes of cancer-related mortality. Up to now, no biomarker 
has been used to predict the prognosis and surveillance of 
patients with colorectal cancer. Recently, the association 
between OPN overexpression and the prognosis of colo-
rectal cancer was investigated widely, but the results were 
inconsistent. Therefore, the aim of meta-analysis by Zhao 
et al. (2015) was to assess the prognostic effect of OPN in 
patients with colorectal cancer. A total of 15 studies showed 
that high OPN expression was significantly associated with 
high tumor grade, lymph node metastasis and tumor distant 
metastasis. What is more, high OPN expression was signifi-
cantly associated with the 2-year, 3-year, 5-year survival rate 
and overall survival, respectively, although the cut-off value 
of high OPN should be further studied. What is really signi-
ficant, the ELISA blood assay may be the best way for OPN 
detection. OPN can be used to evaluate clinicopathology 
of tumor preoperatively and for the surveillance of tumor 
recurrence postoperatively. All these results indicate that 
OPN may serve as a prognostic biomarker and as a potential 
therapeutic target for colorectal cancer [75].
The study by Wu et al. (2014) was also focused on the 
role of OPN in colorectal cancer biology. It was proved that 
knockdown of OPN gene expression suppresses colorectal 
cancer cell growth, adherence, invasion and expression of 
angiogenic factors [76].
Can osteopontin influence stem cells biology?
Hepatocellular carcinoma (HCC) is the fifth most prev-
alent cancer worldwide and as such presents a major glob-
al health burden. Metastasis, tumor recurrence and che-
mo-resistance are among the leading causes of mortality 
of patients with HCC. There is an increasing evidence that 
suggest the HCCs are sustained by a distant subpopulation 
of self-renewing cells know as cancer stem cells. Cao et al. 
(2015) demonstrated that the level of OPN in tumor cells of 
the edge of bulk tumors was significantly correlated with 
the clinical prognosis of patients with HCC. OPN was highly 
expressed in side population fractions of HCC cell lines, as 
well as in dormant cells, spheroids and chemo-resistant 
cancer cells, all of which are considered as having stem-
ness-like cellular features. Depletion of OPN in hepatocel-
lular carcinoma resulted in a reduction in the proportion of 
side population fractions, formation of hepato-spheroids, 
expression of stem-cell-associated genes and decreased 
tumorigenicity. Mechanistically, OPN was demonstrated to 
bind to integrin αvβ3 and activate the transcription factor 
181
NF-κB, which resulted in upregulation of HIF-1α transcription 
and its downstream gene, BMI1, to mediate maintenance of 
the stemness-like phenotype. Suppression of the αvβ3–NF-
κB–HIF-1α pathway decreased OPN-mediated self-renewal 
capabilities. Levels of OPN were significantly correlated with 
HIF-1α protein levels in HCC tumor tissue samples [80]. These 
results indicate OPN might promote a cancer stem cell-like 
phenotype via the αvβ3–NF-κB–HIF-1α pathway. Findings by 
Cao et al. (2015) offer strong support for OPN requirement 
in maintaining stem-like properties in HCC cells [77].
A poor cancer outcome can be associated with 
osteopontin overexpression
Recent studies showed high expression of OPN in NS-
CLC and its association with poor patient outcome. Serum 
OPN levels increased according to tumor pT classification 
and tumor size, and patients with OPN-expressing tumors 
had higher serum OPN levels than patients with OPN-neg-
ative tumors. Rud et al. (2013) showed that tumor OPN 
expression is a strong predictor of poor prognosis, and 
multivariate analysis confirmed OPN as an independent 
prognostic factor. The finding that patients with OPN-ex-
pressing tumors have worse relapse free and overall survival 
than patients with OPN-negative tumors indicates that OPN 
has the potential to be used as a prognostic biomarker in 
NSCLC. The finding that tumor OPN expression, but not 
serum OPN level, was associated with poor survival may be 
clarified by the multi-functionality of OPN [78]. The majority 
of OPN activities ascribed the interaction between secreted 
OPN and its receptors on target cells, however OPN is also 
found intracellularly and the non-secreted form is involved 
in cellular processes such as motility and migration [79, 
80]. Results of the study by Rud et al. (2013) indicated that 
the intracellular levels of OPN are more significant than 
the secreted circulating levels in NSCLC [78]. Furthermore, 
variations in serum OPN measurements may occur due to 
proteolytic cleavage of circulating OPN [81]. Ultimately, OPN 
has an important role in inflammation and wound healing, 
and therefore other systemic sources than the tumor itself 
may affect OPN levels in the circulation.
The finding that OPN-c expression is a predictor of pa-
tient survival in breast cancer, which does not correlate with 
cyclins, receptor status or family predisposition, adds to 
previous reports, that this splice form is an independent bio-
marker. OPN-c showed no association with ER, PR or HER2, 
however it was highly expressed in triple negative breast 
cancer. The multivariate analysis of this study corroborates 
the prior observation that the diagnostic and prognostic 
values may be enhanced by combining OPN-c with the 
receptor status of the cancer. OPN-c in breast cancers was 
reported to correlate with relapse or poor survival [82]. 
According to all these conclusions, the addition of OPN-c im-
munohistochemistry to standard pathology work-ups may 
have prognostic benefit in early breast cancer diagnosis.
Osteopontin promotes resistance to 
chemotherapy
Multidrug resistance is a major cause of chemotherapy 
failure. Recent studies indicate that drug resistance can be 
rapidly induced by some factors, such as cytokines, chemo-
kines, growth factors, and cell adhesion factors in the tumor 
microenvironment. As indicated previously, OPN has a func-
tional arginine-glycine-aspartic acid domain for binding to 
integrin. I-Shan et al. (2013) found OPN expression to be 
upregulated by hypoxic condition in prostatic tumor cells. 
OPN increased the mRNA and protein expression level of 
p-glycoprotein (P-gp), a subfamily of ATP-binding cassette 
transporter in a concentration and time-dependent manner. 
The increase in P-gp expression by OPN was mediated by 
binding to αvβ3 integrin. Daunomycin, a chemotherapeu-
tic agent with autofluorescence, was used to evaluate the 
pump activity, and OPN increased the drug pumping-out ac-
tivity. OPN inhibited daunomycin-induced cell death, which 
was antagonized by αvβ3 monoclonal antibody. Long-term 
treatment with daunomycin further enhanced the expres-
sion of OPN. Knockdown of endogenous OPN potentiated 
the daunomycin-induced apoptosis of prostatic cancer cells. 
Moreover, knockdown of OPN enhanced cell death caused 
by other drugs, including paclitaxel, doxorubicin, actinomy-
cin-D, and rapamycin, which are also P-gp substrates. These 
results indicate that OPN is a potential therapeutic target 
for cancer therapy to reduce drug resistance in sensitive 
tumors [83].
One protein, thousands of interactions
It was proved by Stemberger et al. (2014) that OPN is 
associated with decreased apoptosis in lung adenocarcino-
ma. The level of OPN expression in lung adenociarcinoma 
was associated with decreased apoptotic activity of tumor 
cells (p = 0.006), and correlated with αv integrin expression 
(p = 0.048), particularly in low stage tumors (p = 0.013). 
Study showed that prolonged tumor cell survival in lung 
adenocarcinoma due to OPN and αv integrin overexpression 
may have an impact on tumor progression and resistance to 
therapy [84]. In human lung cancer cells, OPN knockdown 
suppressed lung cancer cell invasion and metastasis and 
also induced autophagy and abrogated the radio-resistance 
of the cancer cells [65]. While OPN concentrations were 
significantly higher in lung cancer patients compared to 
controls, a negative correlation was detected between OPN 
and body mass index (BMI), suggesting that in addition to 
being an indicator of systemic inflammation in lung cancer 
patients, OPN may also be an indicator of advancement of 
the disease and cachexia [86].
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Although OPN has been known as a marker for cancer 
progression, the elevated production of this cytokine is not 
specific only for cancer. Zduniak et al. (2015) have identified 
recently the splice variant OPN-c as being absent from he-
althy tissue but associated with about 75% of breast cancer 
cases. Scientists found that high staining intensity of nuclear 
OPN-c was strongly associated with mortality in patients 
with early breast cancer. Cytosolic staining for exon 4, reflec-
tive of OPN-a and -b variants also predicted poor outcome. 
By contrast, total OPN did not correlate with prognosis. 
These diverse assessments of OPN also did not correlate 
with each other, suggesting distinct expression patterns 
for the variant forms. Consistent with its role in tumor pro-
gression, not tumor initiation, OPN-c is not correlated with 
proliferation markers (Ki-67, cyclin A, cyclin B, cyclin E and 
cyclin D), neither is it correlated with ER, PR or HER2 [82].
Conclusion
There is an increasing number of reports on the role of 
OPN in various medical fields such as oncology, allergology, 
nephrology, and cardiology [87]. Similarly, there are plenty 
of studies that point to a role of OPN in the progression in 
various cancers [88]. Scientists suggest that the knowledge 
of the processes in which OPN is involved may help in the 
diagnosis and prognosis of cancer metastasis, as well as in 
cancer staging and treatment monitoring [89].
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